Cargando…
Maintenance Therapy in AML
Recent advances in therapeutics coupled with steady improvements in supportive care for patients with acute myeloid leukemia (AML) have led to improved outcomes. Despite these advances, even in patients that achieve a complete remission with initial therapy high rates of relapse remain a clinical di...
Autores principales: | Reville, Patrick K., Kadia, Tapan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884813/ https://www.ncbi.nlm.nih.gov/pubmed/33604298 http://dx.doi.org/10.3389/fonc.2020.619085 |
Ejemplares similares
-
Maintenance therapy for AML after allogeneic HCT
por: Nayak, Rahul K., et al.
Publicado: (2022) -
Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series
por: Alotaibi, Ahmad S., et al.
Publicado: (2020) -
Maintenance therapy in acute myeloid leukemia: advances and controversies
por: Senapati, Jayastu, et al.
Publicado: (2023) -
Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022) -
Targeted therapy in NPM1-mutated AML: Knowns and unknowns
por: Wang, Rong, et al.
Publicado: (2022)